Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative.
Alzheimer’s disease
cancer
cognitive impairment
disease progression
mild cognitive impairment
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2020
2020
Historique:
pubmed:
17
6
2020
medline:
8
5
2021
entrez:
16
6
2020
Statut:
ppublish
Résumé
Cross-sectional studies suggest self-reported cancer history is associated with decreased risk of Alzheimer's disease (AD). However, little is known about how self-reported cancer affects longitudinal AD progression, the primary outcome in clinical trials and observational studies. To determine self-reported cancer history's effect on longitudinal AD progression in an observational study. We utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to evaluate progression to AD by self-reported all-cancer, breast, prostate, colorectal, or non-melanoma skin cancer history. Linear mixed effects models were used to examine baseline differences and rates of progression on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) by self-reported cancer history. Age at AD onset was examined using consensus clinical diagnoses with Cox proportional hazards regression. Among 1,271 participants, models revealed no significant differences in progression over time but did reveal significantly lower baseline ADAS-Cog score, indicating better cognition at a given age in those with self-reported cancer history. Cox models indicated those with self-reported cancer history had significantly later age of AD onset (HR: 0.67, 95% CI: 0.53-0.85) after adjustment for covariates. Participants with self-reported cancer history entered ADNI with better cognition and later age of AD onset, but progressed similarly to participants without such history, indicating differences in AD between those with and without self-reported cancer history emerge early in the disease course. Such differences in longitudinal progression by self-reported cancer history could affect AD trials and observational studies, given the current focus on early disease course. Further investigation is warranted with detailed longitudinal assessment of cancer and AD.
Sections du résumé
BACKGROUND
Cross-sectional studies suggest self-reported cancer history is associated with decreased risk of Alzheimer's disease (AD). However, little is known about how self-reported cancer affects longitudinal AD progression, the primary outcome in clinical trials and observational studies.
OBJECTIVE
To determine self-reported cancer history's effect on longitudinal AD progression in an observational study.
METHODS
We utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to evaluate progression to AD by self-reported all-cancer, breast, prostate, colorectal, or non-melanoma skin cancer history. Linear mixed effects models were used to examine baseline differences and rates of progression on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) by self-reported cancer history. Age at AD onset was examined using consensus clinical diagnoses with Cox proportional hazards regression.
RESULTS
Among 1,271 participants, models revealed no significant differences in progression over time but did reveal significantly lower baseline ADAS-Cog score, indicating better cognition at a given age in those with self-reported cancer history. Cox models indicated those with self-reported cancer history had significantly later age of AD onset (HR: 0.67, 95% CI: 0.53-0.85) after adjustment for covariates.
CONCLUSION
Participants with self-reported cancer history entered ADNI with better cognition and later age of AD onset, but progressed similarly to participants without such history, indicating differences in AD between those with and without self-reported cancer history emerge early in the disease course. Such differences in longitudinal progression by self-reported cancer history could affect AD trials and observational studies, given the current focus on early disease course. Further investigation is warranted with detailed longitudinal assessment of cancer and AD.
Identifiants
pubmed: 32538844
pii: JAD200108
doi: 10.3233/JAD-200108
pmc: PMC7928167
mid: NIHMS1673238
doi:
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
691-701Subventions
Organisme : NIA NIH HHS
ID : R01 AG037561
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG057684
Pays : United States
Organisme : CIHR
Pays : Canada
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Références
Neurology. 2015 Mar 17;84(11):1121-7
pubmed: 25681452
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Neurology. 2013 Jul 23;81(4):322-8
pubmed: 23843468
Neurology. 2010 Jan 19;74(3):201-9
pubmed: 20042704
Neurology. 2010 Jan 12;74(2):106-12
pubmed: 20032288
Neurology. 2005 Mar 8;64(5):895-8
pubmed: 15753432
Cancer. 2007 Jan 1;109(1):146-56
pubmed: 17131349
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Cancer Treat Rev. 2013 May;39(3):297-304
pubmed: 23219452
BMJ. 2012 Mar 12;344:e1442
pubmed: 22411920
BMC Geriatr. 2014 Jan 28;14:10
pubmed: 24472217
Alzheimers Dement. 2009 Sep;5(5):388-97
pubmed: 19751918
JAMA Netw Open. 2018 Nov 2;1(7):e184080
pubmed: 30646339
Alzheimers Dement. 2014 May;10(3):349-59
pubmed: 23712001
Am J Epidemiol. 1998 Mar 15;147(6):556-62
pubmed: 9521182
Nucl Med Commun. 2020 Mar;41(3):288-293
pubmed: 31895757
Med Clin North Am. 2017 Nov;101(6):1115-1134
pubmed: 28992858
Front Physiol. 2014 Oct 31;5:423
pubmed: 25400589
Cancer Epidemiol. 2017 Oct;50(Pt A):16-21
pubmed: 28763723
Alzheimers Dement (N Y). 2015 Jun;1(1):46-52
pubmed: 27695707
Am J Psychiatry. 1984 Nov;141(11):1356-64
pubmed: 6496779
J Alzheimers Dis. 2016;50(4):1205-15
pubmed: 26836180
Handb Clin Neurol. 2016;138:297-309
pubmed: 27637965
Curr Alzheimer Res. 2012 Dec;9(10):1135-41
pubmed: 22963265
JAMA Netw Open. 2018 Sep 7;1(5):e181726
pubmed: 30646141
Mayo Clin Proc. 1995 Nov;70(11):1093-107
pubmed: 7475341
Int Rev Psychiatry. 2014 Feb;26(1):102-13
pubmed: 24716504